Document is current

Any future updates will be listed below

Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds

Crossref DOI link: https://doi.org/10.1186/s12962-021-00260-0

Published Online: 2021-02-04

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark